George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- April30 2003
- Volume 10
- Issue 8
HOW MUCH LIFE?
Author(s)Michael Sheehan
Advertisement
Physician'sMoney Digest
How much life insurance do youneed? Most experts agree that 5 to 7times your annual income is a goodbeginning. For average readers, that's nearly$1.5 million in life insurance. Butthat's only a starting point; you needto analyze your own lifestyle andassets to come up with the insurancefigure that best fits you. If you haveseveral young children, you may needmore insurance than if you havefewer or no dependents. If you'reolder with a flush retirement account,you may need less insuranceor none at all. Term life makes moresense for younger doctors than wholelife policies, because you get a biggerbenefit for your buck. Check outinsurance company ratings with A.M.Best (908-439-2200; www.ambest.com) or Weiss Ratings (800-291-8545; www.weissratings.com).
Articles in this issue
about 18 years ago
Portfolio CHECK-UPabout 18 years ago
Don't Delay, Start Saving for Retirementabout 18 years ago
Gain Perspective on Variable Annuitiesabout 18 years ago
Docs Miss the $ Boat-Againabout 18 years ago
Establish E-communication with Patientsabout 18 years ago
Enjoy E-mail Paydays for Consultationsabout 18 years ago
Confront HIPAA as a Former Soviet Wouldabout 18 years ago
Take Steps to Avoid IRS' Audit Dragnetabout 18 years ago
Take Fiscal Advice from a Fellow Doctorabout 18 years ago
Doc's Stocks Current StandingsAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5